Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma

Area of Science:

• Oncology
• Immunotherapy
• Radiation Oncology

Background:

• Hepatocellular carcinoma (HCC) incidence is rising globally, with poor outcomes for advanced stages.
• Cancer immunotherapy, particularly immune checkpoint inhibitors (ICIs), has transformed cancer treatment.
• ICIs targeting PD-1 and CTLA-4 restore anti-tumor immunity but face limitations due to immune suppression.

Purpose of the Study:

• To review the current roles of PD-1 and CTLA-4 therapies in cancer treatment, including HCC.
• To explore the potential of combining ICIs with radiation therapy (RT) for HCC treatment.
• To discuss future perspectives for ICI and RT combination strategies in HCC.

Main Methods:

• Literature review of preclinical and clinical studies on ICIs and RT in various cancers.
• Analysis of the immunomodulatory effects of RT and its synergy with ICIs.
• Focus on the application and potential of these combinations specifically in Hepatocellular Carcinoma (HCC).

Main Results:

• ICI monotherapy efficacy is limited by tumor-immune suppressive mechanisms.
• Radiation therapy (RT) can induce immunogenic cell death, enhancing anti-tumor immune responses.
• Preclinical and clinical data support RT-ICI combinations in several cancers, with emerging interest in HCC.

Conclusions:

• ICIs (PD-1, CTLA-4) are established in cancer therapy, including HCC.
• RT is a promising partner for ICIs due to its immunogenic effects.
• Combining ICIs with RT offers a potential novel strategy to improve HCC treatment outcomes.